TY - JOUR
TI - Hypogammaglobulinemia in rheumatoid arthritis patients treated with rituximab: should we switch biologics? Comment on the article by Fraenkel et al
AU - Evangelatos, G.
AU - Moschopoulou, M.
AU - Iliopoulos, A.
AU - Fragoulis, G.E.
JO - Arthritis and Rheumatology
PY - 2022
VL - 74
TODO - 1
SP - 174-175
PB - John Wiley and Sons Inc
SN - 2326-5191, 2326-5205
TODO - 10.1002/art.41938
TODO - antibiotic agent;  C reactive protein;  disease modifying antirheumatic drug;  immunoglobulin A;  immunoglobulin G;  immunoglobulin M;  rituximab;  antirheumatic agent;  biological product;  rituximab, antibiotic therapy;  DAS28;  disease activity;  drug substitution;  drug withdrawal;  follow up;  human;  immunoglobulin blood level;  immunoglobulin deficiency;  immunotherapy;  Letter;  rheumatoid arthritis;  risk factor;  treatment switching;  agammaglobulinemia, Agammaglobulinemia;  Antirheumatic Agents;  Arthritis, Rheumatoid;  Biological Products;  Humans;  Rituximab
TODO - null
ER -